MASI.NASDAQMasimo CORP
10-Q: Masimo Reports Q1 2025 Results, Announces Sale of Non-Healthcare Business Amidst Cybersecurity Incident
Sentiment:
Quarterly Report
Masimo Corporation announces its Q1 2025 financial results, highlighted by a revenue increase and the strategic decision to sell its non-healthcare business to HARMAN International, while also addressing a recent cybersecurity incident.
Delay expectedThe cybersecurity incident in April 2025 temporarily impacted manufacturing facilities and order fulfillment.
Worse than expectedThe company reported a net loss of $170.7 million compared to a net income of $18.9 million in the same period last year.The loss from discontinued operations was $217.9 million, primarily due to impairment charges.
Summary
- Masimo Corporation reported a net loss of $170.7 million for the first quarter ended March 29, 2025, compared to a net income of $18.9 million for the same period in 2024.
- Total revenue increased by 9.5% to $372.0 million, driven by growth in both direct/distribution and OEM sales channels.
- The company has classified its non-healthcare consumer business as held-for-sale and reported it as discontinued operations, with a definitive agreement to sell the business to HARMAN International for $350 million in cash.
- Masimo experienced a cybersecurity incident in April 2025, which temporarily impacted manufacturing facilities and order fulfillment.
- The company is taking measures to restore normal business operations and mitigate the impact of the incident.
- The company's healthcare segment revenue was $371.0 million, compared to $339.6 million in the same period last year.
- The company shipped approximately 72,200 noninvasive technology boards and instruments, compared to approximately 50,400 during the three months ended March 30, 2024.
- Gross profit increased to 62.9% compared to 60.8% for the same period last year due to operational efficiencies and product cost reductions.
- Selling, general and administrative expenses increased by 3.2% to $119.4 million.
- Research and development expenses decreased by 10.3% to $33.9 million.
- The company had approximately $321.2 million of available borrowing capacity under its Credit Facility as of March 29, 2025.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While revenue increased, the company reported a significant net loss and is dealing with a cybersecurity incident. The sale of the non-healthcare business is a positive strategic move, but the overall tone is cautious due to the financial losses and operational challenges.
Positives
- Total revenue increased by 9.5% to $372.0 million.
- Gross profit margin improved to 62.9% from 60.8% due to operational efficiencies and product cost reductions.
- The company is selling its non-healthcare business to HARMAN International for $350 million, allowing it to focus on its core healthcare operations.
- The company shipped approximately 72,200 noninvasive technology boards and instruments, compared to approximately 50,400 during the three months ended March 30, 2024.
Negatives
- The company reported a net loss of $170.7 million, a significant decrease compared to the net income of $18.9 million in the same period last year.
- The loss from discontinued operations was $217.9 million, primarily due to impairment charges.
- A cybersecurity incident in April 2025 temporarily impacted manufacturing facilities and order fulfillment.
Risks
- The cybersecurity incident could have a lasting impact on manufacturing, order fulfillment, and the company's reputation.
- Changes in trade policies and tariffs could negatively affect the company's costs and sales.
- The healthcare market is highly competitive and subject to economic headwinds, including supply chain volatility and inflationary pressures.
- Ongoing conflicts and wars in Russia, Ukraine, Israel, and Iran could disrupt business in those regions.
- The company is involved in several legal proceedings, including litigation with Apple and shareholder lawsuits, which could result in significant costs and liabilities.
Future Outlook
The company expects to complete the sale of its non-healthcare business to HARMAN International by the end of 2025, subject to regulatory approvals. The company anticipates that its existing cash and cash equivalents, amounts available under its Credit Facility and cash provided by operations, taken together, provide adequate resources to fund on-going operating and capital expenditures, working capital requirements, and other operational funding needs for the next 12 months.
Management Comments
- We aim to accelerate our growth strategies by continuously innovating and prioritizing patient care with a lens toward value-creation initiatives.
Industry Context
The healthcare market is highly competitive and dynamic, experiencing headwinds such as supply chain volatility, inflationary pressures, and rising energy costs. Masimo is focusing on profitability and maximizing return on invested capital to drive stronger returns for stockholders.
Comparison to Industry Standards
- The document does not contain specific comparisons to industry standards or benchmarks.
- Without specific comparables, it's difficult to assess Masimo's performance against industry peers.
- A more detailed analysis would require comparing Masimo's growth rate, profitability, and financial metrics to companies like Medtronic, Philips, and GE Healthcare.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | Michelle Brennan (Interim) | Catherine Szyman | February 12, 2025 | Appointment of permanent CEO |
| Chairman of the Board | Joe Kiani | Michelle Brennan | February 12, 2025 | Board appointment |
| Vice-Chairman of the Board | H Michael Cohen (Lead Independent Director) | Politan Nominee (Koffey) | February 12, 2025 | Board appointment |
| Board Member | Craig Reynolds | NA | April 29, 2025 | Not nominated for reelection |
Legal Proceedings
- Masimo is involved in ongoing litigation with Apple regarding patent infringement and trade secrets.
- The company is facing a securities class action lawsuit and derivative actions related to alleged false and misleading statements.
- Masimo received subpoenas from the Department of Justice and the Securities and Exchange Commission related to product recalls and potential accounting irregularities.
- The company is involved in litigation with former CEO Joe Kiani regarding his employment agreement and termination.
- Masimo is pursuing litigation against RTW Investments for alleged short-swing profits.
Related Party Transactions
- Masimo has a cross-licensing agreement with Willow Laboratories, Inc., where former CEO Joe Kiani is the Chairman and CEO.
- The company made payments to Politan Capital Management LP, which has representatives on Masimo's Board of Directors.
- Sales to Cardinal Health, where board member Michelle Brennan also sits on the board, were approximately $31.8 million.
Stakeholder Impact
- Shareholders are impacted by the net loss and the ongoing legal and operational challenges.
- Employees may be affected by the cybersecurity incident and the strategic realignment initiative.
- Customers could experience disruptions in order fulfillment due to the cybersecurity incident.
- Suppliers may be impacted by changes in trade policies and tariffs.
Next Steps
- Complete the sale of the non-healthcare business to HARMAN International.
- Restore normal business operations and mitigate the impact of the cybersecurity incident.
- Continue to defend intellectual property and pursue legal claims against Apple.
- Respond to the DOJ and SEC subpoenas and investigations.
- Respond to shareholder requests and defend against derivative actions.
Key Dates
| Date | Description |
|---|---|
| 1998 | Willow Laboratories, Inc. spun off from Masimo. |
| January 1, 2007 | Cross-Licensing Agreement with Willow amended and restated. |
| July 19, 2007 | 2007 Severance Protection Plan became effective. |
| December 31, 2008 | 2007 Severance Protection Plan amended. |
| November 4, 2015 | Employment agreement between Masimo and Joe Kiani entered into. |
| June 1, 2017 | 2017 Equity Plan ratified and approved; 2007 Equity Plan terminated. |
| April 11, 2022 | Masimo entered into a credit agreement (Credit Facility). |
| May 16, 2022 | Masimo entered into the First Amendment to the Credit Agreement. |
| June 2022 | Board approved a stock repurchase program. |
| July 2022 | 2022 Repurchase Program became effective. |
| January 14, 2022 | Masimo entered into the Second Amendment to the Amended Employment Agreement with Mr. Kiani. |
| February 8, 2023 | Mr. Kiani agreed that the valid election to the Board at the Companys 2023 Annual Meeting of Stockholders of any two individuals nominated by the Companys stockholders in lieu of two of the Companys then-current Board members would not be deemed to constitute a Change in Control for purposes of Section 9(iii) of the Amended Employment Agreement. |
| March 22, 2023 | Mr. Kiani voluntarily irrevocably and permanently waived his right to treat the appointment of any lead independent director as Good Reason to terminate his employment under the Amended Employment Agreement, and waived his right to receive contractual separation payments on this basis. |
| April 4, 2023 | District Court held a jury trial on the trade secret, ownership, and inventorship claims. |
| May 1, 2023 | District Court declared a mistrial because the jury was unable to reach a unanimous verdict. |
| May 5, 2023 | The Court ordered that the two cases be coordinated through the pre-trial stage. |
| June 5, 2023 | Mr. Kiani, pursuant to a Limited Waiver (Waiver), unconditionally, irrevocably and permanently waived his right, pursuant to the Amended Employment Agreement, to assert that a Change in Control has occurred pursuant to Section 9(iii) of the Amended Employment Agreement unless the individuals who constituted the Board at the beginning of the twelve (12) month period immediately preceding such change, as defined in Section 9(iii) of the Amended Employment Agreement, cease for any reason to constitute one-half or more of the directors then in office. |
| June 26, 2023 | Stockholders voted to elect two directors nominated by Politan Capital Management LP to the Board. |
| August 22, 2023 | A putative class action complaint was filed by Sergio Vazquez against the Company and members of its management alleging violations of the federal securities laws (Securities Class Action). |
| October 26, 2023 | The ITC issued a Notice of Final Determination finding a violation of Section 337 by Apple. |
| January 1, 2024 | The Company entered into a one year alternative fee agreement (Fee Agreement) with respect to certain on-going legal fees and costs charged by a vendor. |
| January 12, 2024 | The U.S. Customs and Border Protection Exclusion Order Enforcement Branch issued a ruling letter allowing importation of certain Apple Watches with the blood oxygen feature disabled. |
| February 14, 2024 | The Company initiated a voluntary recall. |
| February 21, 2024 | The Company received a subpoena from the Department of Justice (DOJ) seeking documents and information related to the Companys Rad-G and Rad-97 products, including information relating to complaints surrounding the products and the Companys decision to recall the Rad-G . |
| March 25, 2024 | The Company received a civil investigative demand from the DOJ pursuant to the False Claims Act, 31 U.S.C 3729-3733, seeking documents and information related to customer returns of the Companys Rad-G and Rad-97 products, including returns related to the Companys recall of select Rad-G products in 2024. |
| March 26, 2024 | The Company received a subpoena from the Securities and Exchange Commission dated March 26, 2024 seeking documents and information relating to allegations of potential accounting irregularities and internal control deficiencies from former employees within the Companys accounting department. |
| April 29, 2024 | The Company moved to dismiss the amended complaint on April 29, 2024. |
| May 1, 2024 | A purported stockholder of the Company, Linda McClellan, filed a derivative action in the U.S. District Court for the Southern District of California against certain of the Companys current and former executives and directors, and the Company as nominal defendant. |
| May 16, 2024 | A purported stockholder of the Company, Dianne Himmelberger, filed a similar derivative action in the U.S. District Court for the Southern District of California (collectively, Derivative Actions). |
| July 15, 2024 | The Company commenced litigation against Politan, Mr. Koffey and Ms. Brennan, members of the Board, in the U.S. District Court for the Central District of California seeking, among other things, an order declaring that Politans proxy materials for the Companys 2024 Annual Meeting of Stockholders violated Section 14(a) of the Securities Exchange Act of 1934, as amended (Exchange Act), enjoining Politan from voting any proxies received by means of Politans misleading proxy materials, invalidating any proxies Politan obtained pursuant to the misleading proxy materials, and requiring Politan to correct material misstatements and omissions the proxy materials. |
| July 22, 2024 | The Court consolidated the Derivative Actions and stayed them until the motion to dismiss the Securities Class Action has been (i) denied in whole or in part, and no amended complaint is subsequently filed; or (ii) granted with prejudice, and any appeals pertaining to the motion to dismiss have concluded, or the time for seeking appellate review has passed with no further action from the Securities Class Action parties. |
| September 9, 2024 | The District Court denied the Companys motion for a preliminary injunction after a hearing on September 9, 2024. |
| September 19, 2024 | At the Companys 2024 Annual Meeting of Stockholders, the Companys stockholder voted not to reelect Mr. Kiani to the Board. |
| September 23, 2024 | Mr. Kiani delivered a notification to the Board further describing his decision to resign (the September 23 Notice), and, on September 25, 2024, Mr. Kiani delivered an amended notification to the Board stating his decision to resign (the September 25 Notice, and, together with the September 19 Notice and the September 23 Notice, the Notice). |
| September 24, 2024 | Michelle Brennan appointed Interim CEO. |
| October 7, 2024 | The Court granted summary judgment dismissing on the Companys inequitable conduct defense and counterclaim. |
| October 2024 | The Court held a jury trial in October 2024 on Apples patent claims. |
| October 24, 2024 | The Board adopted resolutions to terminate Mr. Kianis employment for cause, effective October 24, 2024. |
| October 25, 2024 | The Company commenced litigation in the United States District Court for the Southern District of New York against Mr. Kiani, Roderick Wong, Naveen Yalamanchi, RTW Investments, LP, RTW Investments GP, LLC, RTW Master Fund, Ltd., RTW Offshore Fund One, Ltd., RTW Onshore Fund One, LP, RTW Innovation Master Fund, Ltd., RTW Innovation Offshore Fund, Ltd., RTW Innovation Onshore Fund, LP, and RTW Fund Group GP, LLC, seeking disgorgement of short-swing profits pursuant to Section 16(b) of the Exchange Act (the RTW Litigation). |
| November 5, 2024 | The court granted the motion in part, allowing the surviving claims to proceed to discovery. |
| November 13, 2024 | The Company entered into an employment agreement with Michelle Brennan (Brennan Agreement), who the Board appointed Interim CEO on September 24, 2024. |
| December 30, 2024 | The Company filed an amended complaint in the RTW Litigation on December 30, 2024. |
| January 17, 2025 | The Company and Ms. Catherine Szyman entered into an offer letter (the Offer Letter) in respect of her service as the next CEO of Masimo, effective as of February 12, 2025 (the Effective Date). |
| January 21, 2025 | The Company announced that the Board appointed Catherine Szyman, as Chief Executive Officer of the Company, effective as of February 12, 2025. |
| January 23, 2025 | The defendants filed motions to dismiss the RTW Litigation on January 23, 2025. |
| January 31, 2025 | Robert Chapek notified the Board of his irrevocable resignation from the Board and all committees thereof, effective as of April 29, 2025. |
| February 4, 2025 | The District Court granted the Companys request for dismissal of the case with prejudice. |
| February 6, 2025 | The Company terminated the employment of Tom McClenahan, the Companys EVP, General Counsel and Corporate Secretary, effective as of February 6, 2025. |
| February 12, 2025 | Michelle Brennan ceased to serve as Interim Chief Executive Officer of the Company, a role that she has held since September 24, 2024. |
| February 28, 2025 | Mr. Kiani notified the Company and the Board that he intends to file claims against them under the California Private Attorney General Act based on the Companys alleged failure to pay Mr. Kiani certain wages upon termination in purported violation of his Amended Employment Agreement, seeking damages in excess of $100 million. |
| March 3, 2025 | The Company filed an Amended Complaint, which alleges that Masimos directors at the time of the initial adoption of the Employment Agreement and subsequent amendments abdicated their fiduciary duties as a matter of Delaware law by approving the Amended Employment Agreement, which contained provisions intended to entrench Mr. Kiani in control of the Company indefinitely. |
| March 4, 2025 | The U.S. government imposed a series of tariffs on many products imported into the U.S. from China, Canada and Mexico. |
| March 14, 2025 | The Court lifted the stay. |
| March 17, 2025 | Mr. Kiani filed a motion to dismiss the Amended Complaint. |
| March 26, 2025 | Craig Reynolds was not nominated for reelection by the Board. |
| April 3, 2025 | The Court issued an order granting the defendants motion to transfer the RTW Litigation to the United States District Court for the Central District of California. |
| April 9, 2025 | The Court entered an order for Plaintiffs to file an Amended Compliant by May 8, 2025, and for Defendants to respond to the Amended Complaint by July 11, 2025. |
| April 27, 2025 | The Company identified unauthorized activity on the Companys on-premise network. |
| April 29, 2025 | Effective April 29, 2025, the date of the 2025 Annual Meeting of Stockholders, Mr. Reynolds ceased to be a member of the Board. |
| May 6, 2025 | The Company announced that it entered into a definitive agreement with HARMAN International, a wholly-owned subsidiary of Samsung Electronics Co., Ltd., to sell its non-healthcare business for an aggregate purchase price of $350 million in cash, subject to certain adjustments. |
| May 8, 2025 | Deadline for Plaintiffs to file an Amended Complaint. |
| May 28, 2025 | The parties intend to participate in a mediation scheduled for May 28, 2025. |
| July 11, 2025 | Deadline for Defendants to respond to the Amended Complaint. |
| November 4, 2025 | A jury trial on the patent infringement claims is scheduled to begin on November 4, 2025. |
| End of 2025 | Expected closing date for the sale of the non-healthcare business to HARMAN International, subject to regulatory approvals. |
Keywords
Masimo, financial results, cybersecurity, non-healthcare business, HARMAN International, revenue, net loss, discontinued operations, patient monitoring, healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.